FGFR2 and infantile convulsions and choreoathetosis: A pivotal trial of derazantinib in iCCA is ongoing in subjects with inoperable or advanced iCCA whose tumors harbor FGFR2 gene fusions or FGFR2 gene mutations or amplifications and who received at least one prior regimen of systemic therapy (NCT03230318).